BioPharmSignal logoBioPharmSignal

Biotech News

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research (GHRS)GH ResearchCompany update

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed

Related news

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

XERSXeris Pharmaceuticals2026-08-26 11:30 EST

Xeris Announces Details for XP-8121 Program Overview Webinar

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

TSHATaysha Gene Therapies2026-08-03 12:00 EST

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

AXSMAxsome2026-07-15 11:00 EST

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

ADXNAddex Therapeutics2026-07-08 05:00 EST

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

PRAXPraxis Precision Medicines2026-06-29 20:30 EST

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

View all latest news

GH Research

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals...

Recent company news

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-04-29 12:00 EST

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GHRSGH Research2026-04-20 13:00 EST

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Stock data

Close
28.72 USD
Market cap
1.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States